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Vitamin K epoxide reductase (VKOR) catalyzes the
conversion of vitamin K 2,3-epoxide into vitamin K in
the vitamin K redox cycle. Recently, the gene encoding
the catalytic subunit of VKOR was identified as a 163-
amino acid integral membrane protein. In this study we
report the experimentally derived membrane topology
of VKOR. Our results show that four hydrophobic re-
gions predicted as the potential transmembrane do-
mains in VKOR can individually insert across the endo-
plasmic reticulum membrane in vitro. However, in the
intact enzyme there are only three transmembrane do-
mains, residues 10–29, 101–123, and 127–149, and mem-
brane-integration of residues 75–97 appears to be sup-
pressed by the surrounding sequence. Results of
N-linked glycosylation-tagged full-length VKOR shows
that the N terminus of VKOR is located in the endoplas-
mic reticulum lumen, and the C terminus is located in
the cytoplasm. Further evidence for this topological
model of VKOR was obtained with freshly prepared in-
tact microsomes from insect cells expressing HPC4-
tagged full-length VKOR. In these experiments an HPC4
tag at the N terminus was protected from proteinase K
digestion, whereas an HPC4 tag at the C terminus was
susceptible. Altogether, our results suggest that VKOR
is a type III membrane protein with three transmem-
brane domains, which agrees well with the prediction
by the topology prediction program TMHMM.
The K vitamins, phylloquinone (K1), menaquinones (K2),
and menadione (K3), are a family of structurally similar, fat-
soluble, 2-methyl-1,4-naphthoquinones. The main function of
vitamin K is to act as a co-factor for the -glutamyl carboxylase
that catalyzes the post-translational carboxylation of specific
glutamic acid to -carboxyglutamic acid (Gla)1 of variety of
vitamin K-dependent proteins (1). Members of the vitamin
K-dependent protein family include coagulation factors (factor
II, VII, IX, X) as well as several other proteins that function in
bone metabolism (2) and signal transduction (3). Concomitant
with -glutamyl carboxylation, the reduced form of vitamin K
(vitamin K hydroquinone) is converted to vitamin K 2,3-ep-
oxide, which must be converted back to vitamin K hydroqui-
none for the reaction to continue because of limited vitamin K
amounts in vivo (4). This cyclic conversion of vitamin K estab-
lishes a redox cycle known as the vitamin K cycle (5).
VKOR is responsible for the conversion of vitamin K 2,3-
epoxide into vitamin K and is highly sensitive to inhibition by
coumarin drugs, such as R,S-warfarin (4-hydroxy-3-(3-oxo-1-
phenylbutyl-coumarin)), the most commonly prescribed oral
anticoagulant. Warfarin inhibition of VKOR reduces the avail-
ability of reduced vitamin K, which reduces the rate of carbox-
ylation and leads to partially carboxylated, inactive vitamin
K-dependent proteins. Since its discovery in 1970 (6), numer-
ous futile attempts to purify the enzyme were reported (7–11).
Attempts to understand the mechanism underlying warfarin-
sensitive vitamin K epoxide reduction have been somewhat
more successful (8, 12–15). Recently, the gene encoding VKOR
was identified independently by our laboratory (16) and that of
Johannes Oldenburg (17). The enzyme was designated VKOR
by us and VKORC1 by Oldenburg and co-workers, who assume
that there is another sub-unit still to be identified (either view
may be correct). VKOR is a 163-amino acid integral membrane
protein with a mass of 18.2 kDa.
To understand the structure/function relationships that de-
fine VKOR activity, it is necessary to understand its membrane
topology, i.e. its specific number of TM segments and their
location relative to the cytoplasm or endoplasmic reticulum.
Several computer programs to predict the topology of membrane
proteins are available (18–21). If the location of one of the termini
is known, the best current program correctly predicts the
topology of 65–70% of those membrane proteins with known
crystal structure (20). The reliability of a given topology predic-
tion is increased if the predictions from a number of different
programs agree (19, 20). Moreover, using C-terminal reporter
fusions, experimental examination of the topology is reliable (22).
In this study, we report an experimental determination of
the membrane topology of VKOR. We first determined the
topology of VKOR using multiple prediction programs. These
predictions were then tested by in vitro translation/cotranslo-
cation of a series of VKOR truncations containing an N-linked
glycosylation reporter tag. Our results suggest that VKOR is a
type III membrane protein with three transmembrane do-
mains. The N terminus of VKOR resides in the lumen of the
endoplasmic reticulum, and the C terminus resides in the cy-
toplasm. The N-terminal domain of VKOR, like many type III
membrane proteins, is relatively short, which facilitates its
transfer into the lumen (23). The main features of our in vitro
experiments were confirmed by experiments with microsomes
derived from insect cells expressing full-length VKOR.
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EXPERIMENTAL PROCEDURES
Materials—All oligonucleotide primers, the NuPAGE pre-cast gel,
and the insect cell expression vector pVL1392 were from Invitrogen.
The in vitro translation vector pSPUTK was obtained from Stratagene
(San Diego, CA). The SP6 mMESSAGE mMACHINE capped mRNA
transcription kit and MEGAClear RNA purification kit were obtained
from Ambion (Austin, TX). Rabbit reticulocyte lysate, amino acid mas-
ter mixture, proteinase K, and ribonuclease inhibitor were obtained
from Promega (Madison, WI). [35S]Methionine, [35S]cysteine, and the
enhanced chemiluminescence Western blotting detection reagents
were from Amersham Biosciences. MES, HEPES, CHAPS, and
phenylmethylsulfonyl fluoride were from Sigma. BacVector-3000
DNA kit was from Novagen (Madison, WI). Taq polymerase and Endo
H were from Roche Applied Science. Trans-Blot transfer medium
PVDF membrane (0.2 m) and biotinylated protein size markers were
from Bio-Rad. All the restriction endonucleases and T4 DNA ligase
were from New England BioLabs (Beverly, MA). Horseradish perox-
idase-conjugated secondary antibody was from Jackson Laboratories
(West Grove, PA). Dog pancreatic microsomal membranes were
prepared as described (24).
Construction of Full-length VKOR Fusions with the NST Reporter
Tag at the N or C Terminus—The gene encoding VKOR was amplified
by PCR using pVL1392-VKOR (16) as the template. A 5-NcoI site and
3-PstI site was introduced into the PCR fragment, and the PCR pro-
duct was cloned into the in vitro translation vector pSPUTK by NcoI/-
PstI to yield pSPUTK-VKOR. The N-terminal glycosylation acceptor
tag with the amino acid sequence of MGGNSTGGSGGSGGSG was
obtained by annealing the oligonucleotides 5-CATGGGTGGGAACAG-
CACCGGTGGGAGCGGGGGCAGCGGGGGCAGCGG-3 and 5-CATG-
CCGCTGCCCCCGCTGCCCCCGCTCCCACCGGTGCTGTTCCCAC-
C-3 followed by ligation to NcoI-digested pSPUTK-VKOR. Joining the
vector and the insert by ligation destroys the NcoI site at the 3 end of
the insert. This plasmid was named pSPUTK-NST-VKOR. A C-
terminal glycosylation acceptor tag with the amino acid sequence of
SGGSGGSNSTGGSG was obtained by annealing the oligonucleotides
5-AAGCGGGGGCAGCGGTGGGAGCAACAGCACCGGGGGTAGCG-
GTCTGCA-3 and 5-GACCGCTACCCCCGGTGCTGTTGCTCCCACC-
GCTGCCCCCGCTTTGCA-3 followed by ligation to PstI-digested
pSPUTK-VKOR. In this case ligation of the PstI-cleaved pSPUTK-
VKOR to the insert results in the destruction of the PstI site at the 5
end of the insert. This plasmid is named pSPUTK-VKOR-NST. A dimer
C-terminal glycosylation tag was engineered by first ligating the insert
itself and then ligating the product to PstI-digested pSPUTK-VKOR
plasmid to yield pSPUTK-VKOR-NST2.
Construction of VKOR Truncations with NST Reporter Tag at the N
Terminus—Site-directed mutagenesis was performed to remove the
endogenous BamHI site (without affecting the amino acid sequence) at
365 nucleotides of the VKOR cDNA from pSPUTK-NST-VKOR. The
resulting plasmid was used as the PCR template to generate various
C-terminal truncations of VKOR. A sense oligonucleotide comprising a
NcoI site and part of the NST tag-coding sequence was used as 5
primer for all the PCR reactions. Oligonucleotides containing a BamHI
site and various antisense sequences corresponding to the C terminus of
the predicted TM domains were used as 3 primers for the PCR reaction.
PCR-amplified fragments containing each of the predicted TM domains
and the N-terminal glycosylation reporter tag were cloned into the
NcoI/BamHI-cleaved pSPUTK vector.
Construction of VKOR Truncations with NST Reporter Tag at the C
Terminus—The C-terminal glycosylation acceptor tag with the se-
quence of SGGSGGSNSTGGSG was amplified by PCR using the above
pSPUTK-VKOR-NST plasmid as template. A 5-BamHI site and a
3-EcoRI site were introduced into the PCR fragment, and the resulting
PCR product was cloned to pSPUTK by BamHI/EcoRI to yield pSPUTK-
NST. Various VKOR truncations (containing each of the predicted TM
segments) were then amplified by PCR from the pSPUKT-NST-VKOR
plasmid with the deleted endogenous BamHI site. The 5 primer encod-
ing the start sequence of VKOR includes a NcoI site. All the 3 primers
were the same as above. PCR products were cloned into NcoI/BamHI-
cleaved pSPUTK-NST to yield different VKOR truncations with the
glycosylation reporter tag at the C terminus. The 3-BamHI
(GGATCC) site introduced two amino acid residues (glycine and
serine) between the VKOR truncations and the NST tag. Construct
1–74/98–130-NST was obtained by connecting the PCR fragment of
1–74 and 98–130. Fragment 1–74 was amplified by using the above 5
primer and a 3 primer containing part of the antisense sequence of
VKOR ending at amino acid residue 74 with a XbaI site. Fragment
98–130 was amplified by a 5 primer containing a XbaI site with part
of the sense coding sequence of VKOR starting from residue 98 and
the above 3 primer used for VKOR truncation 1–130. The two ob-
tained PCR fragments were ligated simultaneously with NcoI/
BamHI-cleaved pSPUTK-NST vector to yield the construct of
pSPUTK-NST-1–74/98–130.
A C-terminal glycosylation tag with a sequence of NSTGGGS, which
does not contain the flexible extension linker, was fused to the VKOR
truncation of 1–130 by PCR to yield pSPUTK-1–130-NST. The 5
primer used is the same as above, and the 3 primer contains part of the
C-terminal antisense sequence of 1–130 VKOR truncation and the
antisense sequence of the tag with a BamHI site. The PCR product was
cloned to pSPUTK by NcoI/BamHI. All the constructs used for in vitro
transcription/translation are shown in Fig. 2.
Construction of the Full-length VKOR Fusions with HPC4 Tag at the
N or C Terminus in Insect Cell Expression Vector—A 12-amino acid
peptide (EDQVDPRLIDGK) of HPC4 epitope (25) was introduced to
either the N or C terminus of full-length VKOR. The HPC4-tagged
VKOR cDNA was subcloned into the EcoRI site of the insect cell ex-
pression vector of pVL1392. The nucleotide sequences of all the con-
structs were confirmed by the DNA sequencing facility at the Univer-
sity of North Carolina at Chapel Hill.
In Vitro Transcription and Translation/Cotranslocation—Before in
vitro transcription the recombinant pSPUTK vectors were linearized at
the BamHI site immediately 3 to the C terminus of all the N-terminal
NST-tagged VKOR truncation fusions or at the EcoRI site immediately
3 to the C terminus of all the C-terminal NST-tagged VKOR truncation
fusions. Capped mRNA was synthesized by SP6 RNA polymerase and
purified by MEGAClear RNA purification kit according to the manu-
facturer’s instructions. The transcription reaction was incubated at
37 °C for at least 5 h to increase the yield of mRNA.
In vitro translations using rabbit reticulocyte lysate, and cotranslo-
cations using RM were performed as described previously (26). The
reactions were performed at 25 °C for 30 min in a final volume of 20 l
containing 10 l of rabbit reticulocyte lysate, 0.5 l of ribonuclease
inhibitor (40 units/l), 0.4 l of a 1 mmol/liter amino acid mixture
without methionine and cysteine, 1.6 l of [35S]methionine (3.7  1013
Bq (1000 Ci/mmol)) at 370 MBq (10 mCi/ml), 1.6 l of [35S]cysteine
(3.7  1013 Bq (1000 Ci/mmol)) at 370 MBq (10 mCi/ml), and 1 g of
capped mRNA with or without 1 eq of RM.
The translation products were chilled on ice and mixed with 30 l of
buffer A containing 110 mmol/liter potassium acetate, 2.5 mmol/liter
magnesium acetate, and 25 mmol/liter potassium-HEPES (pH 7.4). For
deglycosylation, 1 l of Endo H (1 milliunits/l) and 1 l of 5% CHAPS
were added to a 10-l aliquot of the diluted translation products and
incubated for 1 h at 37 °C. Before being subjected to SDS-PAGE anal-
ysis, the samples were precipitated with 2 volumes of saturated
(NH4)2SO4, washed with 5% trichloroacetic acid, and redissolved in 10
l of SDS-PAGE sample buffer.
Expression of HPC4-tagged VKOR in Insect Cells and Protease Di-
gestion of VKOR Microsomes—Full-length VKOR molecules with a
HPC4 tag at either the N or C termini were expressed in insect cells.
Microsomes from cells expressing HPC4-VKOR or VKOR-HPC4 were
prepared as described (27). Microsome protein concentrations were
adjusted to 10 mg/ml. For protease digestion 2 l of proteinase K (1
mg/ml) was added to a 10-l aliquot of freshly prepared microsome in
the presence or absence of 0.5% CHAPS as the final concentration. The
reactions were carried out on ice for 2 h and terminated by adding
phenylmethylsulfonyl fluoride to a final concentration of 3 mmol/liter.
After protease digestion, the microsomes were washed 3 times with
buffer A containing 3 mmol/liter phenylmethylsulfonyl fluoride, and the
pellets were dissolved in SDS sample buffer and subjected to SDS-
PAGE analysis.
NuPAGE and Western Blot Analysis—NuPAGE analysis was per-
formed according to the manufacturer’s instructions under reducing
conditions using 1 MES running buffer (50 mM MES, 50 mM Tris, 1
mM EDTA, and 0.1% SDS (pH 7.3). Samples from the in vitro transla-
tion were subjected to 4–12% gradient NuPAGE. After electrophoresis
the proteins were transferred to a PVDF membrane (0.2 m), and
autoradiography was performed (Amersham Biosciences Storm 840
PhosphorImager). Samples of recombinant HPC4-taged VKOR micro-
some and protease-digested microsome were subjected to 12% Nu-
PAGE and transferred to a PVDF membrane as above. Protein bands
were probed with anti-HPC4 monoclonal antibody followed by a
horseradish peroxidase-conjugated secondary antibody, and the pro-
tein bands were detected using the enhanced chemiluminescence
Western blot reagents.
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RESULTS
Prediction of the Membrane Topology of VKOR by Different
Computer-prediction Algorithms—The membrane topology of
VKOR was predicted using seven different topology prediction
programs (us.expasy.org/tools/#ptm) with the default parame-
ters. The results are listed in Table I. As can be seen, five of the
seven programs predict three TM domains in VKOR, PHD
predicts two, and MEMSAT predicts four TM domains. The five
programs that predict the location of the C terminus all agree
that the C terminus of VKOR is located in the cytoplasm. All
programs except PHD predict that the first TM domain com-
prises residues 10 through 29. The remaining TM domain
predictions are somewhat variable for the different prediction
programs. The combined candidate TM domains in VKOR pre-
dicted by all the programs used are 10–29, 75–97, 101–123,
and 127–149. It has been reported that the reliability of topol-
ogy predictions is greatly increased if different topology predic-
tion methods give the same prediction (19, 20). Therefore, it is
likely that VKOR has three TM domains with the C terminus
located in the cytoplasm and N terminus located in the ER
lumen. Fig. 1 shows the membrane topology prediction and the
probability profile of VKOR by the most commonly used pre-
diction program TMHMM. It predicts that VKOR has 3 TM
domains, 10–29, 101–123, and 127–149, with the orientation of
Nexoplasmic/Ccytoplasmic. One candidate TM domain (75–97), pre-
dicted by other programs but not by TMHMM, is indicated in
Fig. 1.
VKOR Fusions with the N-Linked Glycosylation Reporter
Tag—The glycosylation mapping technique (28) was used in
this study to experimentally determine the membrane topology
of VKOR. A conserved N-linked glycosylation acceptor site
(NST) was introduced at either the N or C termini of the
full-length VKOR or various VKOR truncations. According to
the predicted membrane topology of VKOR, only nine amino
acid residues precede the first candidate TM domain. More-
over, if the last predicted TM domain ends at residue149, as
predicted by TMHMM and MEMSAT, only 13 C-terminal
amino acid residues protrude from the membrane. It has been
reported that half-maximal glycosylation occurs when the ac-
ceptor Asn is 1014 residues away from the membrane (28,
29). Therefore, we added flexible amino acid linkers to extend
the Asn glycosylation acceptor site away from the membrane.
The amino acid sequence of the N-terminal NST tag is MGGN-
STGGSGGSGGSG, and the C-terminal NST tag sequence is
SGGSGGSNSTGGSG. The above extended NST tags were
joined to the N or C terminus of full-length VKOR and to all of
the VKOR truncations except when otherwise stated. In addi-
tion, we fused a dimer C-terminal NST tag at the C terminus of
full-length VKOR (VKOR-NST2). To examine whether the pre-
dicted TM region of 75–97 or 101–123 is the authentic TM
domain, we deleted the predicted TM region of 75–97 in the
fusion of 1–130-NST (1–75/98–130-NST). In addition, we fused
a NST glycosylation tag without the flexible linker (NST-
GGGS) immediately to the C terminus of VKOR truncation
1–130. All the constructs used are shown in Fig. 2.
In Vitro Translation/Cotranslocation of the NST-tagged Full-
length VKOR Fusions—Fig. 3 shows the autoradiograph of the
in vitro translation of the full-length VKOR and NST-tagged
full-length VKOR in the presence and absence of RM. As can be
seen, N-terminal tagged VKOR, NST-VKOR, is glycosylated in
the presence of RM, and the glycosylation product is sensitive
to Endo H treatment, which specifically cleaves N-linked core
sugars. This result indicates that the N terminus of VKOR is
located in the ER lumen. In contrast, neither C-terminal
tagged VKOR (VKOR-NST or VKOR-NST2) is glycosylated
(Fig. 3), suggesting that the C terminus of VKOR is located in
the cytoplasm. These results together suggest that VKOR is a
type III membrane protein with the orientation of Nexoplasmic/
Ccytoplasmic, and it has an odd number of TM domains. This
agrees with the topology model predicted by five of the seven
topology prediction programs listed in Table I. In addition,
neither of the two natural potential glycosylation sites in the
VKOR sequence, Asn-77 and Asn-142, is glycosylated; this is
consistent with the prediction of TMHMM, which indicates
that Asn-77 is located on the cytoplasm side of the membrane,
and Asn-142 is located within the membrane.
Determination of the Signal-anchor Potential of the Predicted
TM Domain by in Vitro Translation/Cotranslocation—Accord-
ing to the computer-generated predictions, there are four po-
tential TM segments in VKOR sequence. Therefore, C-terminal
truncations of VKOR were made after each of the predicted
potential TM segments. The N-linked glycosylation reporter
tag was fused to either the N terminus or the C terminus of
these truncations (Fig. 2). Fig. 4 shows the in vitro translation/
cotranslocation results obtained from these NST-tagged VKOR
truncations in the presence and absence of RM and the pro-
FIG. 1. TMHMM topology prediction and probability profile
for VKOR. The top line shows the predicted topology with the predicted
TM helices. The thin black and gray curves show the posterior proba-
bilities for the inside and outside loops, respectively. The striped profile
shows the probability for TM helix. Several other algorithms were also
used for VKOR topology prediction as described under “Results,” a
potential TM region predicted by other programs is indicated as TM? in
this figure.
TABLE I
Prediction of membrane topology of VKOR by different membrane topology prediction programs
Membrane topology of VKOR was predicted by different predication programs using the default parameters. The combined four candidate TM
domains are listed. Numbers under the TM correspond to the amino acid residue of VKOR.
Programs TM no. C terminus TM1 TM2 TM3 TM4
PHD 2 Ina 85–109 (1.0)b 119–143 (0.87)
TMHMM 2.0 3 In 10–29 (1.0) 101–123 (0.90) 127–149 (0.93)
TopPred 2 3 In 9–29 (0.65) 78–98 (0.67) 109–129 (1.0)
TMPred 3 In 9–29 (0.81) 75–97 (0.57) 101–129 (1.0)
DAS 3 12–27 83–96 102–146
SOSUI 3 11–31 (primary) 75–97 (secondary) 116–138 (primary)
MEMSAT 4 In 13–29 (0.76) 81–97 (0.60) 104–124 (1.0) 131–148 (0.68)
a In, cytoplasmic location of ER.
b Numbers in the parentheses are the probability of the predicted TM segment servers as the stop-transfer sequence.
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posed topological orientation. As can be seen, NST-1–40 was
glycosylated, but 1–40-NST was not, indicating that the first
predicted TM segment, 10–29, can function as a reverse signal-
anchor sequence, characteristic of type III membrane protein.
Both fusions of NST-1–100 and 1–100-NST were glyco-
sylated, indicating that both the N and C termini are located
in the ER lumen with the hairpin structure. Together with
the result of fusion 1–40, this result suggests that the second
predicted TM domain, 75–97, can function as a signal-anchor
sequence. However, both fusions of NST-1–130 and 1–130-
NST, which has one more predicted TM domain than fusion
1–100, are also glycosylated, indicating that they have the
same topological orientation as fusion 1–100. This result
raises the question of whether the additional predicted TM
domain of 101–123 in the fusion of 1–130 functions as the
signal anchor sequence.
Predicted TM Region of 101–123 Functions as a Genuine TM
Domain—To examine whether the predicted TM region of 101–
123 functions as a genuine TM domain, we deleted the poten-
tial TM region of 75–97 in the fusion of 1–130-NST (1–75/98–
130-NST) (Fig. 2). As shown in Fig. 5A, the C-terminal
glycosylation tag can be glycosylated in the presence of RM,
indicating that the C terminus is located in the lumen of ER.
Together with the result of fusion 1–40, this result suggests
that the predicted TM region of 101–123 functions as a genuine
TM domain in the fusion 1–75/98–130-NST.
In a further attempt to determine which of the potential
TM domains, 75–97 or 101–123, functions as the genuine TM
domain in the VKOR truncation 1–130, a glycosylation re-
porter tag with the sequence of NSTGGGS was fused to the
C terminus of VKOR-1–130 (1–130-NST). This places the
Asn glycosylation acceptor site immediately after the pre-
dicted TM segment 101–123. According to the “minimum
glycosylation distance” rule (28, 29), this tag should not be
glycosylated if 101–123 functions as the stop-transfer se-
quence in this construct. On the other hand, if 75–97 serves
as a TM domain, this tag should be glycosylated since there is
enough extension sequence between the Asn acceptor site
and the TM segment. As shown in Fig. 5B, no glycosylated
product was detected in the presence of RM. This result
suggests that the predicted TM segment 101–123 is the func-
tional TM domain in the VKOR truncation 1–130, but 75–97
does not.
Independent Determination of the Topological Orientation of
N and C Termini of VKOR in Vivo—To determine the topolog-
ical orientation of the N and C termini of VKOR in vivo, we
constructed two full-length recombinant VKOR molecules
tagged with a HPC4 epitope at either end, HPC4-VKOR and
VKOR-HPC4. Both VKOR constructs expressed in insect (Sf9)
cells displayed kinetic parameters characteristic of the non-
tagged VKOR, indicating correct folding of the recombinant-
tagged enzymes (data not shown). Freshly prepared micro-
somes from the Sf9 cells expressing these constructs were
subjected to proteinase K digestion in the presence or absence
of 0.5% CHAPS and subjected to NuPAGE analysis. The pro-
tein bands were transferred to a PVDF membrane and probed
with the anti-HPC4 antibody and visualized by enhanced
chemiluminescence reagents.
As shown in Fig. 6, proteinase K digestion of the HPC4-
VKOR revealed a protected fragment (indicated by an arrow),
that was rendered sensitive to proteinase K digestion by prior
FIG. 2. Schematic representation of the NST tagged full-length VKOR and VKOR truncation constructs. The solid bars indicate the
TM segments predicted by program TMHMM, and the gray bars indicate the TM segments predicted by other programs listed in Table I. Y
indicates the N-linked glycosylation acceptor sites.
FIG. 3. Localization of the N and C termini of the VKOR in ER
membrane by in vitro translation/cotranslocation. In vitro trans-
lation/translocation of full-length VKOR and NST-tagged VKOR were
performed in the presence () and absence () of RM. Endo H treat-
ment was performed in the presence of 0.5% CHAPS.
FIG. 4. Analysis of the individual predicted TM segments. In
vitro translation/translocation of NST-tagged VKOR truncations were
performed in the presence () and absence () of RM. Endo H treat-
ment was performed in the presence of 0.5% CHAPS. Possible orienta-
tion of each truncation was elucidated on the bottom.
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CHAPS treatment. This indicates the lumenal location of the
HPC4 tag and, therefore, the N terminus of the VKOR. In
contrast, no protease-protected fragment was observed when
microsomes expressing VKOR-HPC4 were treated with pro-
teinase K. This is consistent with the cytoplasmic location of
the HPC4 tag and, therefore, the C terminus of the VKOR.
These data together suggest that VKOR has a topological ori-
entation of Nexoplasmic/Ccytoplasmic that is in agreement with the
above in vitro translation/cotranslocation results.
DISCUSSION
Determining the membrane topology, i.e. specification of
its TM segments and their cytoplasmic/exoplasmic orienta-
tion relative to the membrane, is an important first step in
understanding the function of any integral membrane en-
zyme. Rost et al. (17) suggested that there are three TM
domains in VKORC1, whereas Li et al. (16) suggested that
there may between one-to-three TM domains depending on
the programs used for the membrane topology prediction.
Recently, Goodstadt et al. (30) suggested that rather than the
one-to-three TM domain model, there are four TM domains in
VKOR. All of the previous predictions were based upon to-
pology prediction programs; therefore, in this study we at-
tempt to resolve this issue experimentally.
First, to identify the most likely TM domain candidates, we
used seven different computer programs to predict the mem-
brane topology of VKOR. Five of seven programs agree that
VKOR has three TM domains with the N terminus located in
the lumen and C terminus located in the cytoplasm; however,
the programs that predict three TM domains do not agree on
their location. One program predicts two TM domains in
VKOR, whereas another predicts four. We designed experi-
ments to determine which of the four potential TM domains are
real. To accomplish this we employed the in vitro glycosylation
mapping assay (28, 29).
In the presence of canine rough microsomes, full-length
VKOR as well as VKOR truncations with N-terminal NST tags
are glycosylated by the in vitro translation/cotranslocation sys-
tem. These results strongly suggest that VKOR is a type III
membrane protein with its N terminus in the ER lumen. This
interpretation was confirmed by the observation that an HPC4
tag at the N terminus of full-length VKOR in intact insect
microsomes was protected from protease digestion unless the
membrane was first solubilized with CHAPS. In addition, the
result with NST-1–40 indicates that the first predicted TM
segment (10–29) is authentic. Thus, the location of the N ter-
minus of VKOR and the position of the first TM domain
is established.
The authenticity of the next two predicted TM domains,
residues 75–97 and 101–123, is less clear. Both the N- and
C-terminal NST tags of VKOR-1–100 and 1–130 are glycosy-
lated in the in vitro canine rough microsome system. This
result indicates that the C termini of both truncations are
located in the lumen of the ER (Fig. 4). Because the first
predicted TM domain (10–29) is authentic, the implication of
these results is that the second predicted TM domain (75–97) is
real in VKOR-1–100. Furthermore, based on these results
there is no reason to assume that it is not also a real TM
domain in VKOR-1–130. However, according to the prediction
programs, residues 101–123 have a higher probability of func-
tioning as a TM domain than do residues 75–97 (Table I).
Therefore we tested whether 101–123 functions in vitro as a
TM domain by deleting residues 75–98 from VKOR-1–130-NST
(1–74/98–130-NST). In this construct the C-terminal NST tag
is still glycosylated in the presence of RM (Fig. 5A); this result
indicates that the third predicted TM domain (101–123) can
also function as an authentic TM domain. Together, these
results suggest that in vitro the second and the third predicted
TM domain both can function as TM domains. Which, then, is
functional in VKOR-1–130 and the intact protein?
As mentioned above, the topology prediction programs indi-
cate that residues 101–123 have a higher probability of being a
TM domain than do residues 75–97. To further examine this
question experimentally, we made a NST-tagged fusion of
VKOR-1–130 that did not have a flexible linker; that is, the Asn
glycosylation acceptor site was placed immediately after resi-
due 130 (1–130-NST). If the third predicted TM domain is a
functional TM domain, then this fusion should not be glycosyl-
ated because of insufficient distance between the Asn acceptor
and TM segment (4, 5). As shown in Fig. 5B, no glycosylation
product was observed in the presence of RM, suggesting that
the third predicted TM domain is real in VKOR-1–130-NST.
This result is again consistent with the notion that residues
101–123 and not 75–97 constitute the functional TM domain in
VKOR-1–130 and in the intact protein.
The result of in vitro translation/co-translocation of NST
tagged full-length VKOR (Fig. 3) demonstrates that the N-
terminal NST tag can be glycosylated, but the C-terminal tag
cannot. Despite these results, it is still formally possible that
the C terminus resides in the lumen and that the failure to
glycosylate the NST tag at the C terminus of full-length VKOR
is because of its close proximity to the membrane or to low
glycosylation efficiency (31). Therefore, we fused a dimer NST
tag to the C terminus of full-length VKOR (VKOR-NST2). If the
C terminus really was luminal, then the additional tag should
extend the Asn acceptor site away from the membrane to allow
glycosylation. However, even with this construct, no glycosyla-
tion was observed in the presence of RM (Fig. 3). Therefore, we
conclude that the C terminus of intact VKOR is exposed on the
FIG. 5. Evidence that the predicted TM domain 101–123 is the
third transmembrane segment. A, the second predicted TM region of
75–97 was deleted in the VKOR truncation fusion of 1–130-NST (1–74/
98–130-NST). In vitro translation/translocation was performed in the
presence () and absence () of RM. Endo H treatment was performed
in the presence of 0.5% CHAPS. B, a NST glycosylation tag was directly
fused to the C terminus of VKOR truncation 1–130, which places the
Asn glycosylation site immediately after the predicted TM segment of
101–123 (1–130-NST). In vitro translation/co-translocation of 1–130-
NST was performed in the presence () and absence () of RM. Endo
H treatment was performed in the presence of 0.5% CHAPS.
FIG. 6. Localization of the N and C termini of the VKOR in vivo.
Freshly prepared intact microsomes from insect cells expressing HPC4-
VKOR or VKOR-HPC4 were subjected to proteinase K (PK) digestion in
the presence () and absence () of 0.5% CHAPS. Samples were frac-
tionated by reducing SDS-PAGE, and protein bands were transferred to
PVDF membrane for Western blot. The anti-HPC4 antibody was used
as the secondary antibody for the Western blot analysis. Microsome
membrane protected band was marked by an arrow.
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cytoplasmic side of the ER. The fourth predicted (the third
functional) TM domain (127–149) functions as a genuine TM
domain in intact VKOR. Further evidence that the C terminus
of VKOR resides in the cytoplasm was provided by experiments
where an antibody tag (HPC4) was added to the C terminus of
full-length VKOR (VKOR-HPC4). Intact microsomes were pre-
pared from insect cells expressing VKOR-HPC4 and were treated
with proteinase K. This tag was destroyed by proteinase treat-
ment, whereas a lumenal N-terminal tag was protected (Fig. 6).
Altogether, our data suggest that there are three TM do-
mains (10–29, 101–123, and 127–149) in VKOR and that the N
terminus of VKOR is located in the lumen of the ER, whereas
the C terminus is located in the cytoplasm (Fig. 7). Our results
agree with the membrane topology predicted by most of the
computer prediction programs. The N-terminal domain of
VKOR, like many type III membrane proteins, is relatively
short, which facilitates its transfer into the lumen. Only 12 of
163 amino acids are luminal, whereas 85 residues are located
in the cytoplasm, and 66 residues are buried in the ER mem-
brane. Thus, it seems unlikely that the active site residues
reside in the lumen of ER. Moreover, it seems likely that the
active site is either in the cytoplasm or the membrane itself.
There is a large cytoplasmic loop that includes hydrophilic
and hydrophobic regions and also contains two (Cys-43 and
Cys-51) of the four absolutely conserved cysteines of VKOR.
Goodstadt and Ponting (30) proposed that these two cysteines
were part of the active site of VKOR. However, in their four TM
domain model, the loop containing Cys-43 and Cys-51 is in the
lumen of the ER, whereas in our experimental model this loop
is cytoplasmic. Although the activity of the vitamin K-depend-
ent carboxylase resides in the lumen of the ER, it is possible
that the active site of VKOR could be in the cytoplasm or even
within the membrane as vitamin K is very hydrophobic.
Goodstadt and Ponting (30) proposed that a CXXC motif was
at least part of the active site of VKOR. The CXXC motif is the
active site in a number of thioredoxin and protein disulfide
isomerase enzymes (32). In keeping with this idea, there is
extensive literature detailing the importance of cysteines in the
activity of VKOR (11, 12, 14, 33–38) and that the active site
cysteines reside in a hydrophobic environment (33). Recently,
Wajih et al. (39) reported that mutation of Cys-132 or Cys-135
(the CXXC motif in VKOR) to alanine abolished VKOR activity.
This is consistent with the CXXC motif serving as the redox
center for VKOR. According to our results, the conserved CXXC
motif is located within the third TM domain and is buried in
the membrane.
In conclusion, our results suggest that VKOR is a type III
membrane protein with three TM domains. The majority of the
molecule is located on the cytoplasm side of the ER membrane.
The topology model provides a clear picture of the distribution
of the amino acid residues of VKOR around the ER membrane,
which can be used as the guide for its function study. The
observation that a likely active site motif is within a TM seg-
ment may provide an explanation for the difficulties encoun-
tered in the purification of VKOR (10). That is, its efficient
solubilization may lead to loss of activity.
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